舒尼替尼诱导的甲状腺毒症——并非罕见的病症。
Sunitinib-induced thyrotoxicosis - a not so rare entity.
作者信息
Jazvić Marijana, Prpić Marin, Jukić Tomislav, Murgić Jure, Jakšić Blanka, Kust Davor, Prgomet Angela, Bolanča Ante, Kusić Zvonko
机构信息
Department of Oncology and Nuclear Medicine, University Hospital Centre "Sestre Milosrdnice", Zagreb, Croatia.
Department of Oncology and Nuclear Medicine, University Hospital Centre "Sestre Milosrdnice", Zagreb, Croatia
出版信息
Anticancer Res. 2015 Jan;35(1):481-5.
BACKGROUND/AIM: The tyrosine kinase inhibitor (TKI) sunitinib malate is nowadays a standard first-line treatment option for patients with metastatic clear-cell renal cell carcinoma (mRCC). The aim of this study was to evaluate the incidence and clinical course of thyrotoxicosis in our cohort of patients treated with sunitinib.
PATIENTS AND METHODS
Medical records of all patients treated with first-line sunitinib for mRCC at our Institution between November 2008 and March 2014 were retrospectively reviewed. Thyroid function was assessed after every 2 cycles of therapy, during the 2 weeks off period.
RESULTS
Out of the 62 included patients, hypothyroidism has developed during therapy in 12 patients (19%) and it was preceded by thyrotoxicosis in 2 (3.2%).
CONCLUSION
Sunitinib-induced thyrotoxicosis (SIT), a not so rare entity, was followed by hypothyroidism. The patterns of occurrence and possible significance of SIT, as predictive marker of better treatment response to sunitinib, need to be validated in further studies.
背景/目的：酪氨酸激酶抑制剂（TKI）苹果酸舒尼替尼如今是转移性透明细胞肾细胞癌（mRCC）患者的标准一线治疗选择。本研究的目的是评估在我们接受舒尼替尼治疗的患者队列中甲状腺毒症的发生率和临床过程。
患者与方法
回顾性分析了2008年11月至2014年3月期间在我们机构接受一线舒尼替尼治疗mRCC的所有患者的病历。在每2个治疗周期后的停药2周期间评估甲状腺功能。
结果
在纳入的62例患者中，12例（19%）在治疗期间出现甲状腺功能减退，其中2例（3.2%）在甲状腺功能减退之前出现过甲状腺毒症。
结论
舒尼替尼诱导的甲状腺毒症（SIT）并非罕见，随后会出现甲状腺功能减退。SIT的发生模式及其作为舒尼替尼更好治疗反应预测标志物的可能意义，需要在进一步研究中得到验证。
Zotero 插件